Lupron Depot is indicated for the palliative treatment of advanced prostate cancer, for management of endometriosis, in combination with iron for the preoperative treatment of anemia caused by uterine fibroids, and for the treatment of children with central precocious puberty.

Learn more about Lupron Depot by accessing complete prescribing information below and visiting the Lupron Web site.

Learn more about the following conditions:
Prostate Cancer
Endometriosis and Uterine Fibroids
Central Precocious Puberty

Lupron Depot Prescribing Information

Urology
Lupron Depot® - 4 Month 30 mg, Lupron Depot® - 3 Month 22.5 mg, and Lupron Depot® 7.5 mg are indicated for the palliative treatment of advanced prostate cancer. These dosages are not approved for use in women. The most common side effect associated with Lupron Depot is hot flashes. Like other treatment options, LH-RH agonists may cause impotence. Symptoms may worsen over the first few weeks of treatment. Periodic monitoring of PSA and serum testosterone levels is recommended. For further information, please see complete prescribing information below.

Lupron Depot® - 4 Month 30 mg
(leuprolide acetate for depot suspension)

Lupron Depot® - 3 Month 22.5 mg
(leuprolide acetate for depot suspension)

Lupron Depot® 7.5 mg
(leuprolide acetate for depot suspension)

Gynecology
Lupron Depot® - 3 Month 11.25 mg and Lupron Depot® 3.75 mg are indicated for the management of endometriosis and in combination with iron for the preoperative treatment of anemia caused by uterine fibroids. Side effects associated with Lupron Depot are generally those related to hypoestrogenism, including vasomotor flushes, headaches, and vaginal dryness. In endometriosis studies, after 6 months of therapy with Lupron Depot 3.75 mg, vertebral bone density decreased by an average of 3.2%, compared with pretreatment value. In uterine fibroid studies, a small amount of bone loss (average 2.7% at month 3) was seen during therapy. For further information, please see complete prescribing information below.

Lupron Depot® - 3 Month 11.25 mg
(leuprolide acetate for depot suspension)

Lupron Depot® 3.75 mg
(leuprolide acetate for depot suspension)

Pediatric
Lupron Depot-PED® 7.5 mg, 11.25 mg, and 15 mg are indicated for the treatment of children with central precocious puberty. In clinical studies, the most frequently reported adverse event related to therapy with Lupron Depot-PED was an injection site reaction seen in 5% of children in combined studies. The recommended starting dose of Lupron Depot-PED is 0.3 mg/kg/4 weeks (minimum 7.5 mg). Inadequate dosing may result in poor control of the pubertal process. For further information, please see complete prescribing information below.

Lupron Depot-PED®
(leuprolide acetate for depot suspension)
7.5 mg, 11.25 mg and 15 mg